News Releases

Year

Mar 16, 2023

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

Reported JELMYTO® full year 2022 net product revenues of $64.4 million , an increase of 34% from full year 2021 Completed enrollment of the ENVISION Phase 3 pivotal clinical trial for UGN-102 for LG-IR-NMIBC Topline data readout from ATLAS clinical study and Complete Response from ENVISION pivotal

Mar 09, 2023

UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023

Conference Call and Webcast Scheduled for Thursday, March 16, 2023 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 9, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,

Mar 06, 2023

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 6, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new

Mar 01, 2023

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 1, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in March:

Feb 15, 2023

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

--In a Small Feasibility Study, UGN-102 Achieves a Complete Response in 75% (6 of 8) Patients --UGN-102 is Being Studied in Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 15, 2023-- UroGen Pharma Ltd.

Jan 11, 2023

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 11, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on